This article first appeared on GuruFocus.

Adjusted EBITDA Guidance: Lowered to around 1.9 billion for the full year.

Cash Conversion Rate Guidance: Expected between 30% to 40% for the full year.

Free Cash Flow: Positive free cash flow of around 300 million in Q3.

Networking Capital Reduction: Significant progress in Q3, with further reductions expected in Q4.

Employee Reduction: Number of employees reduced by more than 740 compared to the previous year, primarily in leadership roles.

Warning! GuruFocus has detected 5 Warning Sign with EVKIF.

Is EVKIF fairly valued? Test your thesis with our free DCF calculator.

Release Date: November 04, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Evonik Industries AG (EVKIF) is confident in achieving its revised EBITDA guidance of around 1.9 billion for the year, supported by strong demand in the healthcare segment and improved visibility in order bookings.

The company has made significant progress in reducing its workforce, with 740 fewer full-time employees compared to the previous year, which is expected to contribute to cost savings.

Evonik Industries AG (EVKIF) is on track to meet its free cash flow guidance, with a positive free cash flow of around 300 million in Q3 and further reductions in working capital expected in Q4.

The company is progressing well with its infrastructure carve-out project, which is expected to reduce future capital expenditures and streamline operations.

Evonik Industries AG (EVKIF) is optimistic about the future contributions from its new lipid plant in the United States, which aligns with reshoring initiatives and is expected to enhance EBITDA in the long term.

Evonik Industries AG (EVKIF) faced a weak Q3, with demand remaining very weak across all segments and markets, leading to a reduction in full-year guidance.

The company experienced a significant decline in EBITDA for its advanced technologies segment, attributed to inventory reductions and maintenance shutdown costs.

There is increased competition from Chinese imports in certain product areas, such as silica and crosslinkers, impacting demand and pricing in Europe.

The methionine market remains challenging, with potential new capacities coming online that could suppress prices, despite improvements in cost positions.

The overall macroeconomic environment is expected to remain challenging into 2026, with uncertainties around global trade dynamics and economic conditions.

Q: Can you provide comments on October trading and its support for hitting the 1.9 billion target? Also, there seems to be a gap in the advanced technologies segment's EBITDA. Can you explain this? A: We are confident in reaching our 1.9 billion guidance due to strong demand in healthcare and the absence of Q3's maintenance shutdown costs. September showed improvement, and October is on track. The gap in advanced technologies' EBITDA is due to inventory reductions and maintenance shutdown costs, which impacted fixed cost coverage.

Q: What are the expected bonus provision releases in Q4, and what are the incremental cost savings for 2026? Are there rising imports from Chinese competitors into Europe? A: We don't disclose specific bonus provision details, but they will continue to support earnings. Structural cost savings from reduced FTEs will continue into 2026. Imports from China are rising, affecting areas like silica and crosslinkers, but quantifying the impact is challenging.

Q: How much of the current earnings pressure is due to structural competition, and what are the key moving parts for 2026? A: The pressure is partly due to structural competition, but our specialty businesses are holding up well. For 2026, we expect a challenging macroeconomic environment but see potential improvements from the German stimulus program and our strategic initiatives.

Q: Could you explain the sustainability of the profitability in the infrastructure and other segments? A: The improvement is sustainable due to FTE reductions and streamlining processes. The bonus-related improvements are not sustainable, as we aim for normal bonus levels in the future.

Q: Can you provide details on the lipids business and the timeline for the divestment of the infrastructure segment? A: The new lipids plant in the US is progressing well, and we expect it to contribute positively in the future. The infrastructure segment will be a separate legal entity by January, with options for partnerships or divestment being evaluated next year.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.